+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
17 Oct 2015

US FDA approves BioDelivery Sciences’ sNDA for manufacturing specification change for Bunavail

The US Food and Drug Administration (FDA) has approved BioDelivery Sciences International Inc’s Supplemental New Drug Application (sNDA) for a manufacturing specification change for Bunavail (buprenorphine and naloxone) buccal film (CIII).

Bunavail is a prescription medicine indicated for the maintenance treatment of opioid dependence.

The approval allows for the immediate release of Bunavail inventory to wholesalers. BDSI will be shipping product to wholesalers this morning which should make product available in pharmacies as early as Friday.

What is sNDA? 

Click here to read

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests